A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters.
A clinical drug-drug interaction between famotidine (a H2 receptor antagonist) and probenecid has not been reproduced in rats. The present study hypothesized that the species-dependent probenecid sensitivity is due to a species difference in the contribution of renal organic anion and cation transporters. The transport activities of the H2 receptor antagonists (cimetidine, famotidine, and ranitidine) by rat and human basolateral organic anion and cation transporters [human organic anion transporter (hOAT) 1, hOAT2, r/hOAT3, rat organic cation transporter (rOct) 1, and r/hOCT2] were compared using their cDNA transfectants. The transport activities (Vmax/Km) of famotidine (Km, 345 microM) by rOat3 were 8- and 15-fold lower than those of cimetidine (Km, 91 microM) and ranitidine (Km, 155 microM), respectively, whereas the activity by hOAT3 (Km, 124 microM) was 3-fold lower than that of cimetidine (Km, 149 microM) but similar to that of ranitidine (Km, 234 microM). Comparison of the relative transport activity with regard to that of cimetidine suggests that famotidine was more efficiently transported by hOAT3 than rOat3, and vice versa, for ranitidine. Only ranitidine was efficiently transported by hOAT2 (Km, 396 microM). rOct1 accepts all of the H2 receptor antagonists with a similar activity, whereas the transport activities of ranitidine and famotidine (Km, 61/56 microM) by r/hOCT2 were markedly lower than that of cimetidine (Km, 69/73 microM). Probenecid was a potent inhibitor of r/OAT3 (Ki, 2.6-5.8 microM), whereas it did not interact with OCTs. These results suggest that, in addition to the absence of OCT1 in human kidney, a species difference in the transport activity by hOAT3 and rOat3 accounts, at least in part, for the species difference in the drug-drug interaction between famotidine and probenecid.
Tahara
Harunobu
H
Graduate School of Pharmaceutical Sciences, University of Tokyo, Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Kusuhara
Hiroyuki
H
Endou
Hitoshi
H
Koepsell
Hermann
H
Imaoka
Tomoki
T
Fuse
Eiichi
E
Sugiyama
Yuichi
Y
D000818:Animals; D050482:Catecholamine Plasma Membrane Transport Proteins / Q000502:physiology; D006635:Histamine H2 Antagonists / Q000493:pharmacokinetics*; D006801:Humans; D007668:Kidney / Q000378:metabolism*; D027362:Organic Anion Transport Protein 1 / Q000502:physiology; D027361:Organic Anion Transporters / Q000502:physiology*; D029362:Organic Anion Transporters, Sodium-Independent / Q000502:physiology; D027701:Organic Cation Transport Proteins / Q000502:physiology*; D000075102:Organic Cation Transporter 2; D011339:Probenecid / Q000494:pharmacology; D051381:Rats; D013045:Species Specificity; D013757:Tetraethylammonium Compounds / Q000493:pharmacokinetics
D050482:Catecholamine Plasma Membrane Transport Proteins; D006635:Histamine H2 Antagonists; D027362:Organic Anion Transport Protein 1; D027361:Organic Anion Transporters; D029362:Organic Anion Transporters, Sodium-Independent; D027701:Organic Cation Transport Proteins; D000075102:Organic Cation Transporter 2; C491013:SLC22A2 protein, human; C490280:SLC22A7 protein, human; C493212:Slc22a1 protein, rat; C100590:Slc22a2 protein, rat; D013757:Tetraethylammonium Compounds; C114338:organic anion transport protein 3; D011339:Probenecid